Symbols

ZYME

Zymeworks·NASDAQ

--(--)

ZYME fundamentals

ZYME Q4 2025 Earnings

Zymeworks (ZYME) released its earnings on Mar 2, 2026: revenue was 2.52M (YoY -91.90%), missed estimates; EPS was -0.55 (YoY -77.42%), missed estimates.

Revenue / YoY

2.52M

-91.90%

EPS / YoY

-0.55

-77.42%

Report date

Mar 2, 2026

ZYME Earnings Call Summary for Q4,2025

Clinical Milestone: Zanidatamab demonstrates >1 year PFS and >2 years OS in first-line GEA, with Jazz targeting Q1 2026 BLA submission.
$250M Royalty Financing: Secures non-dilutive capital for growth, with 70% of zanidatamab royalties retained by Zymeworks.
Revenue Growth: 2025 revenue up 39% YoY to $106 million, driven by collaboration milestones.
Share Buybacks: $125M program 50% complete, with plans to continue at current discount.

Earnings

EPS

Revenue

Revenue & Expenses

ZYME has released its 2025 Q4 earnings report, with revenue of 2.52M, reflecting a YoY change of -91.90%, and net profit of -41.21M, showing a YoY change of -75.31%. The Sankey diagram below clearly presents ZYME's revenue sources and cost distribution.

Key Indicators

Zymeworks (ZYME) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Zymeworks (ZYME)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Zymeworks (ZYME)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Zymeworks (ZYME)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown